Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
-
Subject Areas on Research
- Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
- Circulating angiopoietin-2 as a biomarker in ANCA-associated vasculitis.
- Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.
- Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
- Cogan's syndrome and development of ANCA-associated renal vasculitis after lengthy disease remission.
- Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions.
- Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
- Efficacy of remission-induction regimens for ANCA-associated vasculitis.
- Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis.
- Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis.
- Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
- Ocular manifestations of ANCA-associated vasculitis.
- Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
- Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.
- Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.
- Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
- Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis.
- The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
- The informational needs of patients with ANCA-associated vasculitis-development of an informational needs questionnaire.
- Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis.
- Vasculitis and Pregnancy.
- c-ANCA vasculitis after initiation of denosumab.
-
Keywords of People
- Allen, Nancy Bates, Professor of Medicine, Medicine, Rheumatology and Immunology